Suppliers

UGA Biopharma

UGA Biopharma

UGA Biopharma provides customised biosimilar and NBE development services. The well-established platform technology is based on different CHO host cell lines, an optimized expression vector and the proprietary First CHOice® cell culture medium.

UGA Biopharma has successfully completed a large number of biosimilar for several international biopharmaceutical companies. Our know-how and longstanding expertise in cell line development, bioprocess optimization, downstream development and analytics makes us the leading partner for your biosimilar development projects.

Related resource

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...